TEVA.NYSETeva Pharmaceutical Industries LTD
10-Q: Teva Q3 2025: Strong Earnings Turnaround, Debt Reduction
Sentiment:
Quarterly Report
Teva Pharmaceutical Industries Limited reported a significant turnaround in Q3 2025, achieving net income and operating profit, driven by strong U.S. segment performance and substantial debt reduction.
Delay expectedExclusive discussions with a selected buyer for the API business divestiture have terminated, requiring Teva to initiate a renewed sales process, indicating a delay in the planned divestiture.The appeal hearing in the Canadian opioid litigation is scheduled for December 2025, indicating ongoing legal proceedings.The appeal in the Eli Lilly (galcanezumab) patent infringement case had a hearing on September 5, 2025, with a decision still pending.Fact discovery in the Pennsylvania MDL (generic drug antitrust litigation) is scheduled to be completed in December 2025, with bellwether trials set for September 2026 and December 2026, indicating a prolonged litigation timeline.
Capital raiseIn May 2025, Teva issued senior notes in an aggregate principal amount of $700 million bearing 5.75% annual interest and due December 2030.In May 2025, Teva issued senior notes in an aggregate principal amount of EUR 1,000 million (approximately $1,165 million) bearing 4.125% annual interest and due June 2031.In May 2025, Teva issued senior notes in an aggregate principal amount of $500 million bearing 6.00% annual interest and due December 2032.In June 2025, Teva consummated a cash tender offer and extinguished $2,289 million aggregate principal amount of various senior notes.
Better than expectedNet income attributable to Teva turned around from a $437 million loss in Q3 2024 to a $433 million profit in Q3 2025.Operating income significantly improved from a $51 million loss in Q3 2024 to an $882 million profit in Q3 2025.Total debt decreased by nearly $1 billion from December 31, 2024, to September 30, 2025.The U.S. segment, a key market, showed strong revenue growth of 12% and a 25% increase in segment profit.Legal settlements and loss contingencies were substantially lower in Q3 2025 ($60 million) compared to Q3 2024 ($450 million).No goodwill impairment was recorded in Q3 2025, a significant improvement from the $600 million impairment in Q3 2024.
Summary
- Net income attributable to Teva was $433 million in Q3 2025, a significant improvement from a net loss of $437 million in Q3 2024.
- Operating income reached $882 million in Q3 2025, reversing an operating loss of $51 million in Q3 2024.
- Total revenues increased by 3% to $4,480 million in Q3 2025 (1% in local currency) compared to Q3 2024.
- The U.S. segment saw revenues increase by 12% to $2,483 million and segment profit rise by 25% to $937 million.
- Total debt decreased to $16,790 million as of September 30, 2025, from $17,783 million at December 31, 2024.
- Launched four new generic products in the U.S. in Q3 2025, including the first generic GLP-1 for weight loss (liraglutide injection).
- FDA approved AJOVY for episodic migraine in children and adolescents in August 2025.
- FDA approved UZEDY for maintenance treatment of bipolar 1 disorder in adults on October 10, 2025.
- No goodwill impairment charges were recorded in Q3 2025, compared to $600 million in Q3 2024.
Sentiment
Score: 7
Explanation: The company demonstrated a strong financial turnaround in Q3 2025 with significant improvements in net income and operating profit, coupled with substantial debt reduction and key product approvals/launches. However, ongoing legal challenges, a decrease in operating cash flow, and uncertainty around the API divestiture temper the overall positive sentiment.
Positives
- Net income turnaround: $433 million in Q3 2025 vs. -$437 million in Q3 2024.
- Operating income turnaround: $882 million in Q3 2025 vs. -$51 million in Q3 2024.
- U.S. segment revenue growth: +12% to $2,483 million in Q3 2025.
- U.S. segment profit growth: +25% to $937 million in Q3 2025.
- Strong performance of key innovative products: AUSTEDO revenues +38% to $601 million, AJOVY revenues +27% to $73 million, UZEDY revenues +24% to $43 million in U.S. segment (Q3 2025).
- Successful generic launches in the U.S., including the first generic GLP-1 for weight loss (liraglutide injection).
- Significant debt reduction: $16,790 million as of Sept 30, 2025, down from $17,783 million at Dec 31, 2024.
- Improved gross profit margin: 51.4% in Q3 2025 vs. 49.6% in Q3 2024.
- No goodwill impairment in Q3 2025, compared to $600 million in Q3 2024.
- Lower legal settlements and loss contingencies: $60 million in Q3 2025 vs. $450 million in Q3 2024.
- Total equity increased to $7,254 million as of September 30, 2025, from $5,380 million as of December 31, 2024.
Negatives
- Cash flow generated from operating activities decreased to $369 million in Q3 2025 from $693 million in Q3 2024.
- Free cash flow decreased to $515 million in Q3 2025 from $922 million in Q3 2024.
- Europe segment revenues decreased by 2% (10% in local currency) to $1,235 million in Q3 2025.
- International Markets segment revenues decreased by 9% (10% in local currency) to $557 million in Q3 2025, mainly due to Japan divestment.
- Increased R&D expenses (+7%), S&M expenses (+5%), and G&A expenses (+6%) in Q3 2025.
- Intangible asset impairments increased to $64 million in Q3 2025 from $28 million in Q3 2024.
- Uncertainty regarding the divestiture of the API business, as exclusive discussions with a selected buyer terminated.
- Ongoing restructuring efforts include expected headcount reductions of approximately 8% of the total workforce by the end of 2027.
Risks
- Ability to successfully compete in the marketplace, including dependence on generic products, customer base concentration, and competition for innovative medicines.
- Significant indebtedness may limit ability to incur additional debt or make new investments.
- Impact of global economic conditions, macroeconomic developments, and public health crises.
- Significant disruptions of information technology systems, including cybersecurity attacks.
- Interruptions in the supply chain or problems with internal or third-party manufacturing.
- Challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism (e.g., Russia-Ukraine, Middle East conflicts).
- Failure to comply with complex legal and regulatory requirements and changes, including healthcare regulation reforms (OBBBA, U.S. Executive Orders).
- Increased legal and regulatory action in connection with public concern over opioid medications, including ability to make required payments and provide generic Narcan.
- Scrutiny from competition and pricing authorities around the world, including compliance with the DPA with the U.S. Department of Justice.
- Potential liability for intellectual property right infringement and product liability claims.
- Potential significant increases in tax liabilities and the effect on the overall effective tax rate.
- Exposure to currency fluctuations and restrictions, as well as credit risks.
- Potential impairments of long-lived assets, including goodwill.
- Impact of any future failure to establish and maintain effective internal control over financial reporting.
- Failure to achieve sustainability performance targets could lead to interest rate increases or one-time premium payments on sustainability-linked bonds.
- Uncertainty regarding the ultimate timing or structure of a potential divestiture of the API business.
Future Outlook
Teva expects to continue focusing on growing its innovative portfolio, aligning capital allocation, and modernizing operations under the 'Accelerate Growth' phase of its Pivot to Growth strategy. The company anticipates achieving cost savings through Transformation programs, including headcount reductions and optimizing external spend, with an expected reduction of approximately 8% of the total workforce by the end of 2027. The CMS agreement on AUSTEDO maximum fair price is expected to be announced in November 2025, with revised prices effective January 1, 2027, for eligible Medicare patients. The AR Facility is anticipated to be extended during November 2025 for an additional three-year term, maintaining a commitment amount of $950 million. Teva expects to have sufficient cash resources to support its debt service payments and all other financial obligations within one year. The company does not expect the One Big Beautiful Bill Act or OECD BEPS Pillar Two rules to have a material impact on its 2025 consolidated financial statements or effective tax rate in the foreseeable future.
Management Comments
- "We are transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business."
- "For over 120 years, our commitment to bettering health has never wavered."
- "We continued to execute on the four key pillars of our Pivot to Growth strategy, announced in May 2023, which entered into its second phase in 2025."
- "During this second phase of Accelerate Growth, we expect to focus on growing our innovative portfolio, aligning capital allocation to invest in activities we expect to have the highest value, and modernizing our organization and operations to drive both efficiency and cost savings."
- "We are initiating a renewed sales process [for the API business], maintaining our strategic intention to divest its API business."
Industry Context
The pharmaceutical industry continues to see growth in biosimilars and innovative medicines, as evidenced by Teva's focus on these areas and new product approvals/launches. The approval of liraglutide injection marks Teva's entry into the generic GLP-1 market for weight loss, a rapidly expanding therapeutic area. The anti-CGRP class for migraine treatment (AJOVY) and treatments for Huntington's disease and tardive dyskinesia (AUSTEDO) remain competitive, with Teva showing market share growth in AJOVY. The ongoing scrutiny over pharmaceutical pricing, particularly from government bodies like CMS (AUSTEDO price negotiation), reflects broader industry trends towards cost containment and affordability. The continued legal challenges related to patent infringement and antitrust issues highlight the complex regulatory and competitive landscape in the pharmaceutical sector.
Legal Proceedings
- Teva is liable for $235.5 million in patent infringement damages to GSK for carvedilol, with a trial for equitable issues pending.
- Ongoing Multi-District Litigations (MDLs) related to nitrosamine impurities in valsartan, losartan, metformin, and ranitidine products, with a metformin settlement awaiting court approval.
- Antitrust litigation regarding generic Effexor XR, Lamictal, Niaspan, modafinil (European Commission fine of EUR 60.5 million upheld), HIV drugs, COPAXONE (EU fine of EUR 462.6 million appealed), hydrocortisone (UK CMA fines), Revlimid, EpiPen/NUVIGIL, QVAR (settlement in principle), and Xifaxan.
- Deferred Prosecution Agreement (DPA) with the DOJ for antitrust violations, requiring a $225 million fine, pravastatin divestiture, and $50 million in product donations.
- Settlement agreement with the DOJ Civil Division for $25 million to resolve False Claims Act allegations.
- Nationwide opioid settlement agreement finalized for up to $4.25 billion over 13 years (including product donations) and a separate $126 million cash / $49 million product settlement with hospitals.
- Ongoing opioid-related lawsuits in Canada, with class certification granted in British Columbia and Quebec.
- Shareholder litigation related to COPAXONE/DOJ PAP allegations, with class certification granted and an appeal denied.
- Environmental proceedings in India with a $1.4 million penalty, currently under appeal.
- Patent infringement lawsuit against Eli Lilly & Co. for galcanezumab, where a jury verdict in Teva's favor was reversed, and Teva's appeal is pending.
- Antitrust lawsuits against Amarin (Vascepa) and Corcept/Optime (Korlym) are in initial stages, with motions to dismiss and discovery ongoing.
- Motions to approve derivative actions seeking monetary damages against certain past and present directors and officers have been filed in Israeli Courts.
Related Party Transactions
- Purchase of shares from non-controlling interests in a Teva subsidiary in Switzerland.
- Declaration of dividends to non-controlling interests in Teva's subsidiary in Bulgaria.
- Dividends to non-controlling interests in Teva's business venture in Japan.
Stakeholder Impact
- Shareholders: Positive impact from increased net income and equity, debt reduction, and new product approvals; potential negative impact from ongoing litigation costs and uncertainties, and restructuring.
- Employees: Negative impact from planned headcount reductions (approximately 8% of total workforce by end of 2027) as part of Transformation programs.
- Customers: Benefit from new generic and biosimilar product launches (e.g., generic Saxenda, SIMLANDI, SELARSDI); potential impact from AUSTEDO price negotiations with CMS.
- Suppliers: Participation in supplier finance programs indicates ongoing relationships; potential impact from supply chain optimization efforts.
- Creditors: Positive impact from significant debt reduction and adherence to RCF covenants; sustainability-linked bond terms introduce risk if environmental targets are not met.
Next Steps
- Initiate a renewed sales process for the API business.
- CMS agreement on AUSTEDO maximum fair price expected to be announced in November 2025.
- Revised AUSTEDO prices set by the U.S. Government will become effective January 1, 2027.
- Evaluate plans to launch UZEDY in other countries around the world.
- Appeal hearing in the Canadian opioid litigation scheduled for December 2025.
- Briefing on Amarin's motion for judgment on the pleadings in the Vascepa antitrust case expected to be completed by November 19, 2025.
- Fact discovery in the Pennsylvania MDL (generic drug antitrust litigation) scheduled to be completed in December 2025.
- Humana bellwether case in the Pennsylvania MDL set for trial starting in September 2026.
- IRP bellwether case in the Pennsylvania MDL set for trial starting in December 2026.
- Anticipate extension of the U.S. AR Facility during November 2025 for an additional three-year term.
- Continue to execute on the Pivot to Growth strategy, focusing on growing the innovative portfolio, aligning capital allocation, and modernizing the organization and operations.
- Implement Transformation programs to achieve cost savings, including headcount reductions of approximately 8% of the total workforce by the end of 2027.
Key Dates
| Date | Description |
|---|---|
| 2007-09-01 | Teva began selling its carvedilol tablets (generic Coreg). |
| 2008-07-01 | Teva launched its generic version of Lamictal. |
| 2010-07-01 | Teva launched its generic version of Effexor XR. |
| 2012-01-01 | Teva entered into the first settlement with an ANDA filer for generic NUVIGIL. |
| 2013-09-01 | Teva launched its generic version of Niaspan. |
| 2013-11-01 | Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable (LAI) products. |
| 2014-05-01 | More than 3,500 complaints filed by various governmental agencies and private plaintiffs in U.S. state and federal courts with respect to opioid sales and distribution against Teva affiliates and other pharmaceutical companies. |
| 2016-12-01 | Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. for ATTENUKINE technology. |
| 2017-12-01 | Teva last paid dividends on its ordinary shares or American Depositary Shares (ADSs). |
| 2018-07-01 | Teva and its subsidiaries became parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. |
| 2018-09-01 | AJOVY received marketing approval in the United States. |
| 2019-04-01 | AJOVY received marketing approval in Europe. |
| 2020-08-01 | Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. |
| 2021-10-01 | Teva announced a license agreement with MODAG GmbH providing Teva with an exclusive global license to develop, manufacture and commercialize emrusolmin (TEV-286) and TEV-287. |
| 2022-06-02 | Final approval from the court for the $420 million settlement in the Ontario Teachers Securities Litigation. |
| 2022-11-07 | Teva and a bankruptcy-remote special purpose vehicle (SPV) entered into an accounts receivable securitization facility (AR Facility) with PNC Bank, National Association (PNC). |
| 2022-11-09 | Jury trial regarding three method of treatment patents for galcanezumab resulted in a verdict in Teva's favor, awarding $176.5 million in damages. |
| 2022-11-26 | Teva entered into a license agreement with Biolojic Design Ltd. for BD9 multibody. |
| 2023-04-28 | FDA approved UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. |
| 2023-05-01 | UZEDY launched in the U.S. |
| 2023-05-07 | Teva launched its new Pivot to Growth strategy. |
| 2023-06-01 | Teva finalized and fully resolved its nationwide opioid settlement agreement with the states and litigating subdivisions. |
| 2023-08-21 | Teva USA entered into a 3-year deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ). |
| 2023-09-26 | U.S. District Court for the District of Massachusetts issued a decision that reversed the jury's verdict and damages award in the Eli Lilly case, finding Teva's method of treatment patents to be invalid. |
| 2023-10-03 | Teva entered into an exclusive collaboration with Sanofi to co-develop and co-commercialize duvakitug (anti-TL1A, TEV-574). |
| 2023-11-03 | Court granted plaintiffs motion for class certification in the COPAXONE/DOJ PAP shareholder litigation. |
| 2023-11-09 | Teva entered into a funding agreement with Royalty Pharma plc. to further accelerate the clinical research program for olanzapine LAI (TEV-749). |
| 2023-12-01 | Teva received a civil subpoena from the U.S. Attorney's office in Boston, Massachusetts requesting certain documents related to the sale and marketing of AUSTEDO and risperidone LAI. |
| 2024-01-31 | Teva announced its intention to divest its API business. |
| 2024-02-24 | Alvotech and Teva announced that the FDA approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira. |
| 2024-03-28 | Teva and Launch Therapeutics, Inc. entered into a clinical collaboration agreement to further accelerate the clinical research program of Teva's Dual-Action Asthma Rescue Inhaler (DARI) (ICS-SABA; TEV-248). |
| 2024-04-01 | Takeda informed Teva of its intent to terminate the agreement with respect to modakafusp alfa, with product rights reverting to Teva in Q1 2025. |
| 2024-04-16 | FDA approved SELARSDITM (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara. |
| 2024-04-17 | Alvotech and Teva amended their collaboration agreement to enable the purchase by Quallent of a private label adalimumab-ryvk injection from Alvotech for the U.S. market. |
| 2024-05-03 | Terms of the RCF were amended to update the Company's maximum permitted leverage ratio. |
| 2024-05-08 | Teva and MedinCell announced positive Phase 3 efficacy results from a trial evaluating olanzapine LAI as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia. |
| 2024-05-16 | Third Circuit Court of Appeals denied Teva's petition for leave to appeal class certification in the COPAXONE/DOJ PAP shareholder litigation. |
| 2024-05-20 | Alvotech and Teva announced that SIMLANDI is available in the United States. |
| 2024-05-24 | Amarin filed a motion in the U.S. District Court for the District of Nevada, seeking to enforce the terms of an earlier Teva-Amarin agreement to settle patent litigation regarding Vascepa. |
| 2024-06-14 | Court entered orders bifurcating discovery and limiting the first phase to the question of the timeliness of plaintiffs claims in the EpiPen/NUVIGIL antitrust case. |
| 2024-06-23 | Teva entered into an agreement with the ITA to settle certain litigation with respect to taxes payable for the Company's taxable years 2008 through 2020. |
| 2024-06-26 | Alvotech announced its intention to exercise its redemption rights and redeemed the convertible bonds, which were paid to Teva in July 2024. |
| 2024-07-04 | The One Big Beautiful Bill Act was signed into law in the United States. |
| 2024-07-01 | FDA approved AUSTEDO XR in 18 mg dose. |
| 2024-08-05 | Plaintiffs filed amended complaints in the Revlimid antitrust case. |
| 2024-09-01 | Teva and the representatives for acute care hospitals finalized the terms of a proposed class settlement agreement for opioid-related claims. |
| 2024-09-06 | U.K. Court of Appeal overturned the Tribunals judgment on due process in the hydrocortisone antitrust case. |
| 2024-09-24 | Vermont court granted Teva's motion to transfer the Retailers case to the District of New Jersey in the COPAXONE antitrust litigation. |
| 2024-09-29 | Teva purchased $40 million of subordinated convertible bonds of Alvotech. |
| 2024-10-01 | Teva received a civil investigative demand from the U.S. Attorney's office in Boston, Massachusetts and the Civil Division of the Department of Justice requesting certain documents and information related to the manufacturing practices at its former manufacturing facility in Irvine, California. |
| 2024-10-10 | Teva entered into a settlement agreement with the Civil Division to resolve allegations of market allocation and/or price-fixing, illegal remuneration, and false claims. |
| 2024-10-10 | Teva entered into a settlement agreement with the DOJ to resolve claims related to donations to patient assistance programs. |
| 2024-10-22 | FDA approved SELARSDI in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. |
| 2024-10-29 | SPV amended the AR Facility agreement and increased the commitment amount to a maximum amount of $950 million. |
| 2024-10-31 | European Commission announced its final decision, alleging that Teva had abused a dominant position in certain European member states by filing and withdrawing certain divisional patents, and raising concerns about competitors follow-on versions of COPAXONE, imposing a fine of euro 462.6 million. |
| 2024-11-01 | Teva divested pravastatin pursuant to the DPA with the DOJ. |
| 2024-11-02 | Alvotech announced that the FDA issued a complete response letter (CRL) for the BLA of Alvotech's proposed biosimilar to Simponi (golimumab). |
| 2024-11-17 | DOJ PAP Complaint case dismissed with prejudice. |
| 2024-12-04 | Nevada court denied Amarin's motion to enforce settlement in the Vascepa antitrust case. |
| 2024-12-12 | U.S. District Court for the District of Delaware set a schedule for briefing on legal issues in the carvedilol patent infringement case. |
| 2024-12-17 | Teva and Sanofi announced that the Phase 2b study for duvakitug met its primary endpoints in patients with ulcerative colitis and Crohn's disease. |
| 2024-12-31 | Teva classified its API business as held for sale. |
| 2025-01-01 | Teva repaid $426 million of its 6.00% senior notes due 2025 at maturity. |
| 2025-01-01 | Teva repaid $427 million of its 7.13% senior notes due 2025 at maturity. |
| 2025-01-01 | FDA accepted for review Biologic License Applications (BLA) for Alvotech's proposed biosimilars to Simponi and Simponi Aria (golimumab). |
| 2025-01-04 | Teva appealed the October 2023 judgment regarding the modafinil antitrust fine to the European Court of Justice. |
| 2025-01-22 | British Columbia Supreme Court certified the class of federal and provincial governments in the Canadian opioid litigation. |
| 2025-01-22 | Special Master in the District of New Jersey issued reports and recommendations on Teva's motions to dismiss the direct purchaser plaintiffs (DPP) complaint and the Mylan complaint in the COPAXONE antitrust litigation. |
| 2025-02-01 | FDA accepted for review a BLA for Alvotech's proposed biosimilar to Eylea (aflibercept). |
| 2025-02-21 | Alvotech and Teva announced that SELARSDI was available in the United States. |
| 2025-02-27 | Mylan filed an objection with the District Court to certain of the Special Master's recommendations for dismissal in the COPAXONE antitrust litigation. |
| 2025-03-01 | Teva repaid $515 million of its 4.50% senior notes due 2025 at maturity. |
| 2025-03-04 | Court overseeing the hospital cases granted final approval for the opioid settlement. |
| 2025-03-25 | Amarin filed a pre-motion letter with the District of New Jersey, asking for permission to file a motion for judgment on the pleadings in the Vascepa antitrust case. |
| 2025-03-26 | Briefings on legal issues in the carvedilol patent infringement case were completed. |
| 2025-03-28 | Teva moved for summary judgment limited to the statute of limitations defense in the United Healthcare action based on the DOJ PAP Complaint. |
| 2025-03-31 | Teva divested its business venture in Japan. |
| 2025-04-08 | Supreme Court of India accepted the appeal filed by Teva's subsidiary in the environmental matter. |
| 2025-04-30 | FDA approved SELARSDI (ustekinumab-aekn) injection as interchangeable with the reference biologic Stelara (ustekinumab) in all presentations matching the reference product. |
| 2025-05-01 | Takeda's license agreement with Teva terminated, with all remaining rights to ATTENUKINE technology reverting to Teva. |
| 2025-05-07 | Teva announced its Transformation programs, expecting to achieve cost savings through headcount reductions and optimizing external spend. |
| 2025-05-09 | Interest rate adjustments and potential one-time premium payment related to sustainability-linked bonds become effective if sustainability targets are not met. |
| 2025-05-28 | Humana re-filed the DOJ PAP Complaint case in Kentucky circuit court. |
| 2025-05-30 | DPPs filed an amended complaint in the COPAXONE antitrust litigation. |
| 2025-06-01 | Teva initiated a Phase 1 clinical trial for TEV-287 for Parkinson's disease. |
| 2025-06-01 | Teva consummated a cash tender offer and extinguished $2,289 million aggregate principal amount of senior notes. |
| 2025-06-06 | Court granted in full Celgene's motion to dismiss the Insurer Opt-Out Action in the Revlimid antitrust case. |
| 2025-07-01 | Teva repaid $444 million of its 1% senior notes due 2025 at maturity. |
| 2025-07-28 | Eastern District of New York court granted a motion filed by Teva to transfer the EpiPen/NUVIGIL antitrust case to the District of Kansas. |
| 2025-08-04 | Parties informed the court that they had reached a settlement in principle in the QVAR antitrust case. |
| 2025-08-07 | Special Master issued a report and recommendation on Teva's motion to dismiss the indirect purchasers complaint in the COPAXONE antitrust litigation. |
| 2025-08-11 | Christine Fox, Executive Vice President, U.S. Commercial, adopted a Rule 10b5-1 trading arrangement. |
| 2025-08-19 | District court approved a settlement agreement between Teva and one group of plaintiffs (indirect purchaser plaintiffs) in the generic Effexor XR antitrust case. |
| 2025-08-28 | Teva announced the FDA approval and launch in the U.S. of liraglutide injection (generic Saxenda). |
| 2025-09-05 | Hearing held on Teva's appeal in the Eli Lilly (galcanezumab) patent infringement case. |
| 2025-09-09 | Teva received Fast Track designation from the FDA for emrusolmin (TEV-286). |
| 2025-09-12 | Court denied in substantial part defendants' joint motion to dismiss in the Korlym antitrust case. |
| 2025-09-15 | Interest rate adjustments related to sustainability-linked bonds become effective if sustainability targets are not met. |
| 2025-09-18 | Teva and Eagle filed suit against Almaject, Inc. and Alvogen, Inc. in the District of Delaware following the filing of another 505(b)(2) NDA for a generic BENDEKA product. |
| 2025-09-26 | Teva filed an amended complaint amending certain claims that were dismissed in the Korlym antitrust case. |
| 2025-10-01 | Sanofi and Teva initiated Phase 3 studies for Teva's duvakitug (anti-TL1A) for inflammatory bowel disease. |
| 2025-10-08 | Court granted Amarin's request to file its motion for judgment on the pleadings in the Vascepa antitrust case. |
| 2025-10-09 | Oral argument on the appeal in the HIV drugs antitrust case occurred at the U.S. Court of Appeals for the Ninth Circuit. |
| 2025-10-10 | Teva and MedinCell announced that the FDA approved UZEDY as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar 1 disorder (BD-1) in adults. |
| 2025-10-23 | European Court of Justice issued its judgment, dismissing Teva's appeal regarding the modafinil antitrust fine. |
| 2025-10-29 | Amarin served its motion for judgment on the pleadings in the Vascepa antitrust case. |
| 2025-11-02 | Alvotech announced that the FDA issued a complete response letter (CRL) for the BLA of Alvotech's proposed biosimilar to Simponi (golimumab). |
| 2025-11-05 | Date of this Quarterly Report on Form 10-Q. |
| 2025-11-19 | Briefing on Amarin's motion for judgment on the pleadings in the Vascepa antitrust case is expected to be completed. |
| 2025-11-01 | CMS agreement on AUSTEDO maximum fair price expected to be announced. |
| 2025-12-01 | Hearing on the appeal in the Canadian opioid litigation is scheduled. |
| 2025-12-01 | Fact discovery in the Pennsylvania MDL is scheduled to be completed. |
| 2026-01-01 | Revised prices for AUSTEDO set by the U.S. Government will become effective for eligible Medicare patients. |
| 2026-09-01 | Humana bellwether case in the Pennsylvania MDL is set for trial. |
| 2026-12-01 | IRP bellwether case in the Pennsylvania MDL is set for trial. |
| 2027-01-01 | Teva expects to achieve cost savings through its Transformation programs, including headcount reductions, by the end of 2027. |
| 2027-04-01 | RCF maturity date. |
| 2027-11-17 | Hospira, Accord and DRL can launch their generic bendamustine products. |
Recommendation
holdTeva's Q3 2025 results show a significant financial turnaround, with a return to net income and operating profit, substantial debt reduction, and strong performance in its U.S. segment driven by key innovative products and new generic launches. The company is actively executing its "Pivot to Growth" strategy and addressing its debt load. However, the company faces considerable headwinds, including a decrease in operating and free cash flow, revenue declines in Europe and International Markets (local currency), and a complex web of ongoing, material legal proceedings (opioids, antitrust, patent infringement) that carry significant financial and reputational risks. The uncertainty surrounding the API business divestiture and the planned workforce reductions also add a layer of caution. While the positive momentum is encouraging, the unresolved legal and strategic execution risks warrant a "hold" recommendation, suggesting investors monitor further progress on litigation resolutions and the successful implementation of the growth strategy.
Keywords
Teva, Pharmaceuticals, Generics, Biosimilars, AUSTEDO, AJOVY, UZEDY, Debt Reduction, Q3 2025, Earnings, SEC Filing, 10-Q, Opioids, Antitrust, Pipeline, R&D, Sustainability-linked bonds
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.